| Drug Name |
Miglitol |
| Drug ID |
BADD_D01464 |
| Description |
Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body.
Miglitol should be taken at the start of a meal for maximal effect and the effect will depend on the amount of poly and oligosaccharides in the diet. Miglitol inhibits alpha-glucosidase, making less sugars available for digestion and reducing postprandial hyperglycemia.
Unlike other drugs of the same class, miglitol is not metabolized and the unmetabolized drug is excreted by the kidneys. |
| Indications and Usage |
For use as an adjunct to diet to improve glycemic control in patients with non-insulin-dependent diabetes mellitus (NIDDM) whose hyperglycemia cannot be managed with diet alone. |
| Marketing Status |
Prescription |
| ATC Code |
A10BF02 |
| DrugBank ID |
DB00491
|
| KEGG ID |
D00625
|
| MeSH ID |
C045621
|
| PubChem ID |
441314
|
| TTD Drug ID |
D0D0ZD
|
| NDC Product Code |
57664-684; 76333-126; 67254-616; 71205-936; 76333-127; 57664-686; 69367-305; 69367-304; 71205-935; 71205-937; 69367-303; 57664-685; 76333-125 |
| Synonyms |
miglitol | N-hydroxyethyl-1-desoxy-nojirimycin | N-hydroxyethyl-1-desoxynojirimycin | Diastabol | miglitol, 4-methylbenzenesulfonate salt, ((D)-isomer) | Plumarol | BAY m 1099 | BAY-m-1099 | BAY-m 1099 | Glyset |
